Published in J Physiol on October 20, 2005
Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc Res (2009) 1.80
Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol (2010) 1.64
Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol (2012) 1.44
Biophysical properties of normal and diseased renal glomeruli. Am J Physiol Cell Physiol (2010) 1.07
VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney. J Physiol (2017) 0.98
Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. J Am Soc Nephrol (2014) 0.92
VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol (2012) 0.87
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci (1995) 4.83
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci (1998) 3.80
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Dynamics of glomerular ultrafiltration in the rat. IV. Determination of the ultrafiltration coefficient. J Clin Invest (1973) 2.55
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
The dynamics of glomerular ultrafiltration in the rat. J Clin Invest (1971) 2.27
VEGF(165) mediates glomerular endothelial repair. J Clin Invest (1999) 2.18
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol (2003) 2.00
Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol (2002) 1.95
Preeclampsia: a renal perspective. Kidney Int (2005) 1.82
Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest (1997) 1.79
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol (2001) 1.75
Three-dimensional reconstruction of glomeruli by electron microscopy reveals a distinct restrictive urinary subpodocyte space. J Am Soc Nephrol (2005) 1.72
VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol (1996) 1.70
Structural determinants of glomerular hydraulic permeability. Am J Physiol (1994) 1.68
Permeability of frog mesenteric capillaries after partial pronase digestion of the endothelial glycocalyx. J Physiol (1990) 1.60
Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol (1995) 1.60
Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol (2004) 1.59
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol (2001) 1.54
Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem (1999) 1.45
Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol (1996) 1.43
Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res (1997) 1.42
Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol (1992) 1.41
Pressure in the glomerular capillaries of the rat kidney and its relation to arterial blood pressure. Pflugers Arch Gesamte Physiol Menschen Tiere (1966) 1.40
Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol (2004) 1.29
Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res (2004) 1.24
ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation (2002) 1.18
The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels. J Physiol (1998) 1.02
VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol (2002) 1.01
Structural mechanisms of acute VEGF effect on microvessel permeability. Am J Physiol Heart Circ Physiol (2003) 1.00
Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol (2004) 1.00
Openings through endothelial cells associated with increased microvascular permeability. Microcirculation (1999) 1.00
Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem (1993) 1.00
VEGF stimulates tyrosine phosphorylation of beta-catenin and small-pore endothelial barrier dysfunction. Am J Physiol (1999) 0.97
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol (1999) 0.95
Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide (2004) 0.95
Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol (2000) 0.95
Filtration in single isolated mammalian glomeruli. Kidney Int (1981) 0.91
Increased tubuloglomerular feed-back mediated suppression of glomerular filtration during acute volume expansion in rats. J Physiol (1988) 0.88
Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant (1998) 0.87
A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol (2004) 0.86
Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant (1998) 0.86
Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med (2001) 0.84
Filtration by superficial and deep glomeruli of normovolemic and volume-depleted rats. Am J Physiol (1986) 0.81
In vitro effects of angiotensin II on glomerular function. Am J Physiol (1986) 0.81
Capillary pressure in deep and superficial glomeruli of the rat kidney. Acta Physiol Scand (1977) 0.80
Determinants of glomerular filtration rate in the dog. Am J Physiol (1976) 0.80
Dynamic alterations of glomerular charge density in fixed rat kidneys suggest involvement of endothelial cell coat. Am J Physiol Renal Physiol (2003) 0.76
Glomerular effects of angiotensin II require intrarenal factors. Am J Physiol (1990) 0.76
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 3.19
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 3.03
VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer (2008) 3.02
Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) (2009) 2.31
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci (2008) 2.09
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell (2011) 2.06
Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol (2003) 2.00
Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc Res (2009) 1.80
Three-dimensional reconstruction of glomeruli by electron microscopy reveals a distinct restrictive urinary subpodocyte space. J Am Soc Nephrol (2005) 1.72
VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis (2006) 1.71
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem (2009) 1.68
Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol (2009) 1.67
Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol (2012) 1.44
Incorrect citation. Invest Ophthalmol Vis Sci (2011) 1.41
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res (2008) 1.39
Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett (2006) 1.35
Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J (2007) 1.34
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer (2008) 1.30
Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol (2004) 1.29
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin Sci (Lond) (2006) 1.28
Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol (2005) 1.26
The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol (2008) 1.24
Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol Renal Physiol (2003) 1.24
Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation (2009) 1.22
Evidence for restriction of fluid and solute movement across the glomerular capillary wall by the subpodocyte space. Am J Physiol Renal Physiol (2007) 1.21
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci (2010) 1.20
Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2010) 1.17
VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res (2007) 1.16
VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. Am J Pathol (2013) 1.14
A TRPC-like non-selective cation current activated by alpha 1-adrenoceptors in rat mesenteric artery smooth muscle cells. Cell Calcium (2006) 1.11
The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol (2006) 1.09
The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans (2009) 1.07
VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation (2008) 1.05
Remarkable amphibian biomass and abundance in an isolated wetland: implications for wetland conservation. Conserv Biol (2006) 1.03
New aspects of glomerular filtration barrier structure and function: five layers (at least) not three. Curr Opin Nephrol Hypertens (2009) 1.02
Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J Am Soc Nephrol (2013) 1.00
VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation (2006) 0.99
IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology (2010) 0.98
Flufenamic acid is a tool for investigating TRPC6-mediated calcium signalling in human conditionally immortalised podocytes and HEK293 cells. Cell Calcium (2009) 0.97
Glomerular filtration into the subpodocyte space is highly restricted under physiological perfusion conditions. Am J Physiol Renal Physiol (2007) 0.96
Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS One (2013) 0.95
Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol (2008) 0.94
An adenovirus-mediated gene-transfer model of angiogenesis in rat mesentery. Microcirculation (2004) 0.94
A role for the endothelial glycocalyx in regulating microvascular permeability in diabetes mellitus. Cell Biochem Biophys (2007) 0.94
Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol (2009) 0.93
Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci (2013) 0.92
A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation (2011) 0.91
Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am J Pathol (2008) 0.90
Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. Chem Sci (2011) 0.88
Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol (2010) 0.88
VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol (2012) 0.87
Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo. Cancer Res (2010) 0.87
Therapeutic potential of inhibitory VEGF splice variants. Future Oncol (2005) 0.86
CCR7 mediates directed growth of melanomas towards lymphatics. Microcirculation (2011) 0.85
SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans (2012) 0.83
Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density. BMC Cancer (2010) 0.83
Plasma from women with severe pre-eclampsia increases microvascular permeability in an animal model in vivo. Clin Sci (Lond) (2004) 0.83
Glomerular filtration barrier and molecular segregation: guilty as charged? J Am Soc Nephrol (2010) 0.83
SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2013) 0.83